Related Experiment Video
Updated: Jul 18, 2025
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
The Effect of Metformin on Triple-Negative Breast Cancer Cells and Nude Mice
Abstract:
Triple-negative breast cancer (TNBC) presents the most adverse prognosis due to its pronounced invasive and metastatic features. Existing research has highlighted that metformin, a prevalent diabetes medication, possesses strong anti-tumor properties, particularly in inhibiting tumor invasion and metastasis. This study delves deeper into the impact of metformin on TNBC by examining changes in proliferation, apoptosis, invasion, migration, and adhesion of TNBC cells, specifically MDA-MB-231, post-metformin exposure. The treatment of MDA-MB-231 with metformin in immunodeficient nude mice led to discernible changes in tumor metrics such as size, weight, lymph node engagement, and angiogenesis. Post-treatment, MDA-MB-231 cells exhibited a marked decline in proliferation, invasion, migration, and adhesion, alongside a significant rise in apoptosis. In the in vivo model with nude mice, tumors displayed notable reductions in size and weight post-metformin exposure. Furthermore, there was a pronounced decline in lymph node plasma cell proliferation and tumor angiogenesis. Through the use of both Enzyme-Linked Immunosorbent Assay and Real-Time Fluorescence Quantification, it was ascertained that the expression of Signal Transducer and Activator of Transcription 3 (STAT3) saw significant augmentation, while expressions of Matrix Metallopeptidase-2 (MMP-2), Matrix Metallopeptidase-9 (MMP-9), Interleukin-6 (IL-6), and Interleukin-7 (IL-7) decreased markedly. This suggests metformin's potential efficacy against TNBC, potentially mediated via the STAT3 signaling pathway and interleukins 6 and 7.
Insights
Metformin, a diabetes drug, effectively inhibits triple-negative breast cancer (TNBC) progression. It reduces tumor growth, invasion, and metastasis while increasing cancer cell death, potentially via the STAT3 pathway.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Triple-negative breast cancer (TNBC) has a poor prognosis due to its invasive and metastatic nature.
- Metformin, a common diabetes medication, shows anti-tumor potential, particularly against cancer invasion and metastasis.
Purpose of the Study:
- To investigate metformin's effects on TNBC cell proliferation, apoptosis, invasion, migration, and adhesion.
- To evaluate metformin's impact on TNBC tumor growth, lymph node metastasis, and angiogenesis in vivo.
Main Methods:
- MDA-MB-231 TNBC cells were treated with metformin in vitro and in immunodeficient nude mice.
- Tumor metrics (size, weight, lymph node engagement, angiogenesis) were assessed.
- Cellular assays measured proliferation, apoptosis, invasion, migration, and adhesion.
- ELISA and Real-Time Fluorescence Quantification analyzed STAT3, MMP-2, MMP-9, IL-6, and IL-7 expression.
Main Results:
- Metformin significantly reduced MDA-MB-231 cell proliferation, invasion, migration, and adhesion, while increasing apoptosis.
- In vivo, metformin decreased tumor size, weight, lymph node plasma cell proliferation, and angiogenesis.
- Metformin treatment led to increased STAT3 expression and decreased expression of MMP-2, MMP-9, IL-6, and IL-7.
Conclusions:
- Metformin demonstrates significant anti-tumor efficacy against triple-negative breast cancer.
- The anti-cancer effects may be mediated through the STAT3 signaling pathway and modulation of interleukins 6 and 7.
